After taking weight loss drugs many users find that their faces become bony giving them an unearthly appearance. Now Swiss skin care company Galderma Group AG has an answer for those people who suffer from sunken faces due to using other companies’ formulations: fillers.
The Swiss skin care company is hoping to capitalize on rising demand for drugs like Ozempic, which – while helping people lose weight – can make users look bony. The side effect was dubbed “Ozempic face” on social media after Novo Nordisk’s now-popular drug.
Galderma’s Sculptra skin care product and other fillers “should be able to restore that,” Chief Executive Officer Fleming Ornskov told Bloomberg in an interview after first-quarter earnings.
“I think this is going to be another wave of growth in this space, which I’ll be sure to catch,” he added.
Ossification side effects
Weight loss drugs made by Novo and Eli Lilly & Co. they have become very popular as people rush to find faster and easier ways to lose weight. But many patients “end up with faces that look sunken,” Ornskov said.
Sculptra boosts collagen production, which helps treat wrinkles and other signs of aging.
Ornskov was speaking as the company reported its first earnings as a public company. Galderma, whose brands also include Cetaphil and Alastin, saw sales rise 12 percent to $1.07 billion in the first quarter.
Galderma’s shares have rallied since last month’s IPO, making it one of the year’s most successful initial public offerings amid the recent capital markets drought.
Ornskov, who has been at the helm since 2019, said China is Galderma’s fastest growing market and is on track to become the third or fourth largest by the end of the year. He also identified Japan as the next opportunity, which he is “in the process of attacking”.
Source OT
#Ozempic #face #fix #promises #dermatology #company
